Sunday, 3 May 2020

Cleanroom Technology Market Forecasts By Industry Drivers, Regions Till 2022

Market Scenario:
The growing biotechnology sector is likely to be a major driver for the global cleanroom technology market trends over the forecast period. Biotechnology research and product development require a complete absence of potential contaminants, as even the smallest presence of contaminants can ruin the results of the research or product development efforts. The growing life sciences sector has driven investment in the biotechnology sector in recent years, as disease treatment and other application avenues have come in sharp focus. Increasing government support to the life sciences sector is likely to be the major driver for the global cleanroom technology market over the forecast period.
Cleanroom is basically a controlled environment which has low level of pollutants such as air-born microbes and particles, dust, aerosols which contaminate the surrounding area. Cleanroom technology is used by nearly all the industries in order to avoid the adverse effects caused by the air pollutants and small particles in the manufacturing process of a product. Globally the market for cleanroom technology is growing rapidly. Global cleanroom technology market is expected to show an exponential growth and would reach approximately $4 Billion in 2022.
The increasing pharmaceutical industry is also likely to be a major contributor to the global cleanroom technology market. Increasing efforts to come up with more efficient and effective pharmaceutical formulations are likely to lead to increasing demand from the cleanroom technology market over the forecast period. Other industries are also making increasing use of cleanroom technology in order to enhance the manufacturing process, which is likely to drive the global cleanroom technology market at a strong growth rate over the forecast period.
Key Players    
  • Alpiq Group,
  • Ardmac Ltd,
  • Camfil,
  • Clean Air Products,
  • Helapet Limited,
  • M+W Group GmbH,
  • Nicomac Srl,
  • Royal Imtech N.V.,
  • Simplex Isolation Systems,
  • Taikisha Ltd. and others.
Segmentation:
The global cleanroom technology market is segmented on the basis of equipment, consumable, end user, and region.
The cleanroom technology market has been segmented on the basis of equipment into laminar air flow, HEPA filters, cleanroom air showers, cleanroom filters, desiccator cabinets, particle counters, cleanroom pass through systems, environmental monitoring system, and others.
On the basis of consumables, the market is segmented into head-caps, gloves, face masks, lab suits, footwear, wipes, swabs, disinfectants, and others.
On the basis of end user, the cleanroom technology market is segmented into pharmaceutical industry, biotechnology industry, research laboratories, and others.
Study Objectives of Cleanroom Technology Market:
  • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the cleanroom technology market
  • To provide insights about factors affecting the market growth
  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future prospective
  • To provide country level analysis of the market for segments by equipment, by consumables, by industry and its sub-segments.
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global cleanroom technology market.

Regional Analysis
Globally Americas is the largest market for cleanroom technology. Europe is the second-largest market. Furthermore Asia-Pacific market is expected to be the fastest growing market for cleanroom technology.
The report for cleanroom technology market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Sepsis Diagnostics Market Professional Overview 2020 With Major Vendors Size, Shares And Worldwide Demand

Market Scenario:
An expert on premium research reports, Market Research Future has added a report titled "Global Sepsis Diagnostics Market 2023" to its offering. The report provides an in-depth analysis of regional data and an accurate projection of the market size and share of the Top 10 market players across the globe.
Sepsis is a type of life-threatening organ dysfunction arises when the body's response to an infection injures its own tissues and organs. It can be caused due to weakened immune system, chronic illness, kidney or liver disease, cancer and severe wounds. It can be of two types severe sepsis when there’s organ failure and other is septic shock in which there are the symptoms of severe sepsis includes a low blood pressure. The hospital-acquired infections and rising prevalence of sepsis has led to a growing need for its early diagnosis, which is one of the driving factor for sepsis diagnostics market.
The global market for sepsis diagnostics market size  is expected to reach USD 710 million by the end of the forecasted period and is expected to grow at a CAGR of 8%.
Competitive Analysis
  • bioMérieux, Inc.
  • EKF Diagnostics
  • Immunexpress
  • T2 Biosystems, Inc.
  • Becton
  • Dickinson and Company
  • Axis-Shield Diagnostics Ltd.
  • Cube Dx GmbH
  • Sandstone Diagnostics, Inc.
Study Objectives of Global Sepsis Diagnostics Market:
  • To provide detail analysis of the market structure along with forecast for the next 7 years of various segments and sub-segments of the global sepsis diagnostics market.
  • To provide insights about factors affecting the market growth.
  • To analyze the market based on various factors which includes price analysis, supply chain analysis, Porters Five Force Analysis etc.
  • To offer past as well as estimated future revenue of the market’s  segments and sub-segments with respect to four main geographies and their countries; these includes  Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and estimated future growth of the market.
  • To give country level analysis of the market’s segments which includes by technology, by type of product, by end users and other sub segments.
  • To provide overview about key players and their strategic profiling in the market; comprehensively analyzing their core competencies and drawing a competitive landscape for the market.
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, along with research and developments that is taking place globally.

Segmental Analysis
Global sepsis diagnostics market has been segmented on the basis of technology which comprises molecular diagnostics, biomarkers, immunoassays and others. On the basis of type of product product types; the market is segmented into kits, instruments, blood culture media and others. On the basis of end users the market is segmented into pathology laboratories, specialty clinics, hospitals, diagnostic centers and others.
Regional Analysis
Globally North America is the largest market for medical tourism. The North American market for sepsis diagnostics is expected to reach USD 320 million by the end of the forecasted period.
Europe is the second largest market for sepsis diagnostics which is expected to grow at the CAGR of 6.8%. Asia Pacific is expected to be fastest growing region in sepsis diagnostics market.
The report of global sepsis diagnostics market by Market Research Future comprises of extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts and key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and projected future market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. Along with all these detail information and strategies about top key players in the industry is also given. Further a broad study of different markets segments and regions is also provided.
Industry Updates:
Dec 2018 Beckman Coulter, which is an international leader in the clinical diagnostics industry has announced that it is joining forces with Sepsis Alliance, the nation's leading sepsis organization, to support the Sepsis Coordinator Network. The pioneering online, peer-to-peer alliance for healthcare professionals, the Sepsis Coordinator Network is dedicated to saving lives by advancing patient results.
May 2018 Mobidiag, a Finnish firm, has obtained funding to creäte a rapid molecular sepsis assay on its Novodiag system. The fresh funding comprises of a €1.5 million ($1.74 million) loan for the first year of the project provided by Business Finland, a funding agency previously known as Tekes.

North America Microarray Market Likely Boost The Industry Revenue And Demand Till 2027

North America Microarray Market Information, by type (Protein microarray, tissue microarray, cellular microarray), Tissue microarray by product (paraffin tissue sections (FFPE), frozen tissue sections), by application (immunohistochemistry, in-situ hybridization) - Forecast to 2027
Market Synopsis of North America Microarray Market:
Market Scenario:North America the market for Microarray is increasing rapidly. A microarray is a multiplex lab-on-a-chip. It is a 2D array on a solid substrate, usually a glass slide or silicon thin-film cell, that assays large amounts of biological material using high-throughput screening miniaturized, multiplexed and parallel processing and detection methods. Globally the microarray market is dominated by DNA microarrays. The protein microarray is currently the fastest growing market. The use of peptide and carbohydrate microarrays is expanding. Tissue and cell microarrays are in their infancy stage and are developing slowly because of many complications in the process development. North American market for Microarray is expected to grow at the rate of about 4.0% from 2016 to 2027.
Key Finding
  • The North America microarray market is expected to reach $1,635.4 billion by 2027.
  • Paraffin tissue sections (FFPE) hold the 54.6% of the North America Tissue Microarray market share.
  • U.S. holds the largest market share of North America Tissue Microarray market and is anticipated to reach $364.2 million by the end of 2027.
  • Immunohistochemistry segment holds the largest market share of 47.5% in 2015.
Segments:                                                                                                                                       
North America Microarray market has been segmented on the basis of types which comprises of protein microarray, tissue microarray, and cellular microarray. On the basis of product, North America Tissue microarray market is segmented into paraffin tissue sections (FFPE), frozen tissue sections, and others. On the basis of applications, tissue microarray market is segmented into immunohistochemistry, in-situ hybridization, and others.

Regional Analysis of North America Microarray Market:                                                                
In North America, U.S. is the largest market for Tissue Microarray. Canada is the second-largest market and is expected to be fastest growing market for Tissue Microarray in North America.

Key Players for North America Microarray Market:                                                              
Some of the key players in this North America Microarray Market are: ABCAM, ASTERAND BIOSCIENCE, IHC WORLD LLC, NOVUS BIOLOGICALS LLC (ACQUIRED BY BIO-TECHNE), ORIGENE TECHNOLOGIES INC, PANTOMICS, INC, PROTEIN BIOTECHNOLOGIES INC, US BIOMAX, INC., US BIOUPTON INT, VITROVIVO BIOTECH, LLC and others.

Global Wound Closure Device Market Production, Capacity, Revenue, Price, Gross Margin Analysis And Forecast 2019-2023

Market Scenario:
The timely treatment of wounds has progressed to incorporate non-invasive, disposable, and sterile wound closure solutions. Reports that assess the healthcare industry have been presented by Market Research Future, which creates reports on numerous industry verticals that examine the market progress and forecasts. The market is anticipated to accomplish a CAGR of 6.9 % in the forecast period.
The development of medical devices and treatment procedures for trauma-related injuries is motivating the wound closure device market. The rise in the volume of surgical procedures has increased the wound closure device market growth considerably. The upswing in the cases of trauma, burns, and accidents is stimulating the market for wound closure devices.
Moreover, advancement in technology, decrease in a number of surgical site infections and attempts to reduce hospital stays for reducing surgical expenditure is contributing to the growth of the market. According to a survey conducted by the American Professional Wound Care Association (2017), chronic nonhealing wounds impact nearly 15% of Medicare beneficiaries (8.2 million). The estimated spending for primary wound diagnosis is USD 28 billion per year and the cost for secondary wound diagnosis is estimated to be USD 31.7 billion.  
The risk associated with infectious wounds, side effects of wound closure devices, and unfavorable reimbursement policies may hamper the growth of the market during the assessment period.
Key Players
  • 3M,
  • Abbott Laboratories,
  • Braun Melsungen AG,
  • Ethicon Inc.,
  • ,
  • Smith & Nephew,
  • Baxter International,
  • BSN medical Inc.,
  • Derma Sciences,
  • Kinetic Concepts,
  • ConvaTec,
  • DACH Medical Group,
  • Arthrex GmbH,
  • Gecko Biomedical,
  • Integra LifeScience,
  • CP Medical.
Segmentation
The global wound closure device market has been segmented based on device, application, type of wound, and end-user.
On the basis of device, the market has been classified into adhesives, staples, sutures, and mechanical wound closure devices. Adhesives are furthers classified into fibrin tissue adhesives and cyanoacrylates. The sutures segment has been further divided into absorbable, non- absorbable, braided, and monofilament.
On the basis of application, the market has been classified into burns, ulcers, surgical wounds, pressure ulcers, diabetic ulcers, and arterial ulcers. On the basis of type, the surgical wounds segment has been sub-segmented into chronic wounds, acute wounds, and others.
The market, by end-user, has been segmented into hospitals, community healthcare service providers, ambulatory surgical centers, and home care.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The wound closure device market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European wound closure device market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The wound closure device market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The wound closure device market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas is likely to hold the majority of the global wound closure device market owing to increase in the number of surgical procedures, increasing injuries related to accidents, sports and adventure, aging population, the presence of a well-established healthcare system, and adoption and awareness of the wound closure technology. According to the American Association for the Surgery of Trauma, injury accounts for over 150,000 deaths and over 3 million non-fatal injuries are reported per year in the US.
The European market is expected to be the second-largest wound closure device market after the Americas. The market growth in this region can be attributed to an increase in aged population and rising occurrence of sports injuries and accidents. Moreover, the growing number of road accidents in the European region are contributing to the growth of the market in this region. According to data published by the European Commission in 2018, more than 135,000 people suffered serious injury from road accidents.
Asia-Pacific is expected to be the fastest-growing wound closure device market during the forecast period owing to the significant increase in aged population, increasing prevalence of chronic diseases such as diabetes leading to the increasing cases of diabetic foot ulcer. According to WHO, there are more than 96 million diabetics patients in the Asia-Pacific region.
The market in the Middle East and Africa is expected to account for the smallest share of the global wound closure device market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Pituitary Cancer Market 2019 - Shares, Revenue, Analysis And Forecasts Till 2025

Market scenario:
Among cancers that harm the human body internally, pituitary cancer is a dangerous one where pituitary tumors, due to their abnormal growth in pituitary gland interfere with the secretion of pituitary hormone secretions within the body. The prevalence of this cancer is making its market popular.
Market Research Future (MRFR) has published a research report that prophesizes an increase for the global pituitary cancer market with 9.4% CAGR (Compound Annual Growth Rate) between 2017 and 2023.The key factors driving the growth of this market include the growing geriatric population, increasing research & development (R&D) by key players in the market, and rising healthcare expenditures.
Global Pituitary Cancer Market Research Report: By Cancer Type (Adrenocorticotropic Hormone-Secreting [ACTH] Tumor, Growth Hormone-Secreting Tumor, Prolactin-Secreting Tumor and Thyroid-Stimulating Hormone-Secreting Tumor), Treatment Type (Chemotherapy, Surgery, Radiation Therapy and others), End User (Hospitals & Clinics, Research & Academic Institutes and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025
The global pituitary cancer market has been segmented on the basis of diagnosis, end-user, treatment type, and lastly region. The diagnosis based segmentation of this market covers blood test, brain imaging, urine test, and vision testing. Based on end-users, the market has been segmented into clinics, diagnostic centers, and hospital. By treatment type, the market has been segmented into medications, radiation therapy, and surgery.
The regional segmentation of the global pituitary cancer market segments the market into regional markets namely The Americas (North America & South America), Europe, Asia Pacific, and the Middle East & Africa (MEA). The largest share in the global market is held by the Americas. This market is expected to grow during the forecast period. North America is estimated to lead the market whereas South America is projected to be the fastest growing region for the market. As per the country-wise sub-segmentation of this region, due to advanced medical facilities, growing advancements in the field of neurology, increasing cases of cancer, and robust R & D practices are the key reasons for market growth in the United States of America (USA) and Canada, followed by the rest of North America. Due to technological advancement, North America is a bigger market than South America.
The second largest pituitary cancer market is in Europe. Here, the market is growing due to the adoption of a sedentary lifestyle, increase in workload, growing funds for research, rising patient population, and the presence of many key players in the market. The United Kingdom (UK) and Germany are the major contributors to this market. The other important markets are France, Italy, and Spain, followed by the rest of Western Europe. Due to reasons same as the Americas, Western Europe market is bigger than the Eastern Europe market.
The forecast period estimates the Asia Pacific to emerge as the fastest growing market due to the expanding healthcare sector, favorable government policies, growing patient population, and the presence of economies with rapid growth like China and India. The other important markets in this region include Australia, Japan, and South Korea, followed by the rest of Asia Pacific.
MEA region is the smallest regional market. Due to lack of education, less infrastructure development, limited growth in the healthcare sector, and political instability, the market is low in this region. Maximum revenue for this market is generated by Kuwait, Oman, Qatar, Saudi Arabia, and United Arab Emirates (UAE), followed by rest of the MEA region.
Key Players
The key players in the global pituitary cancer market include Accuray Incorporated (USA), C. R. Bard, Inc. (the USA), Elekta AB (Sweden), Genentech, Inc. (the USA), Ion Beam Applications (Belgium), Isoray Medical, Inc. (the USA), Mevion Medical Systems, Inc. (the USA), Mitsubishi Electric Corporation (Japan), Nordion, Inc. (Canada), RaySearch Laboratories (Sweden), Salzman International (USA) , Sigma-Aldrich Co. LLC (USA), Trinity Biotech (Ireland), and Varian Medical Systems, Inc. (the USA).
Latest Industry News
  • A new test using betamethasone — a corticosteroid that causes the pituitary gland to stop producing ACTH – can accurately predict short- and long-term remission in Cushing’s disease patients who have had pituitary surgery. 10 AUG 2018.

Stroke Disorder and Treatment Market Staggering Double Digit Cagr Till 2022

Globally the market for stroke disorder & treatmentis increasing rapidly.The major factor that derives the stroke disorder & treatment market growth is the increasing high blood pressure patients. Furthermore increasing alcoholism and patients with diabetes, cardiovascular diseases are increasing the growth of Stroke Disorder & Treatmentmarket. Globally the market for Stroke Disorder & Treatmentmarket is expected to grow at the rate of about XX% CAGR from 2016 to 2022.
Heart problems and brain problems are considered among most dangerous medical problems, and their treatments are considered to be most expensive. Heart strokes and brain strokes can strike any moment and can be fatal. Hence, the market offering treatment for it is always lucrative. Globally it is increasing rapidly. The major factor that drives the growth of this market is the increasing high blood pressure patients. Due to increasing alcoholism and patients with diabetes, cardiovascular diseases are increasing the growth of this disorder and the market offering its treatment.
Market Research Future (MRFR) has published a research report about the global stroke disorder and treatment market that estimates huge aggrandizement in this market between 2016 and 2022. This report provides a detailed analysis of the market structure along with a forecast for the next seven years. It analyzes the market on the basis of various factors including porters five force analysis, price analysis, and supply chain analysis. Providing insights about the current market size and future prospects, this report features expert opinions. Profiling the key players in the market, this report covers competitive developments such as joint ventures, mergers and acquisitions, new product developments, strategic alliances, and research and developments in the global market.
The global stroke disorder and treatment market has been segmented into medicines, treatment, types, and lastly region. On the basis of medicines, this market has been segmented into anticoagulants, anti-hypertensive, and antiplatelet. Anticoagulants, also called blood thinners, are chemical substances that prevent or reduce coagulation of blood, prolonging the clotting time. Apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa), enoxaparin (Lovenox), fondaparinux (Arixtra), heparin, rivaroxaban (Xarelto), and warfarin (Coumadin) are some examples of anticoagulants. Antiplatelet is a member of a class of pharmaceutical drugs that decrease platelet aggregation and inhibit thrombus formation. They are more effective in the arterial circulation compared anticoagulants. Examples of antiplatelet include clopidogrel (Plavix), dipyridamole/aspirin (Aggrenox), eptifibatide (Integrilin), prasugrel (Effient), ticagrelor (Brilinta), and ticlodipine (Ticlid). Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure). Examples of antihypertensives include benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec), lisinopril (Zestril and Prinivil), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), and trandolapril (Mavik).  
Treatment-based segmentation of the market covers tissue plasminogen activator (TPA) and endovascular procedures. TPA is an enzyme involved in the breakdown of blood clots and dissolves them. The endovascular procedure is surgery. Being innovative, it is a less invasive procedure, popularly used for treating problems affecting the blood vessels, such as an aneurysm, which is a swelling or “ballooning” of the blood vessel. By types, the market has been segmented into hemorrhagic strokes and ischemic stroke. The weakened blood vessel leakage is called a hemorrhagic stroke. Its two categories are aneurysms and arteriovenous malformations. Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain.
The regional segmentation of global stroke disorder and treatment market cover North America, Europe, and the Asia Pacific. The key players of this market are primarily based in these continents. In other parts of the world, the market for stroke disorder and treatment is limited due to less advanced medical facilities, little investment in health care, lack of awareness about stroke disorder, and poor infrastructure. In North America and Europe, investments in research and development (R & D) and advanced medical facilities boost this market. According to this report, the market in North America is expected to rise and earn maximum revenue by the end of the forecast period. Europe is the second largest market. The Asia Pacific is expected to be the fastest growing market for stroke disorder and treatment because some countries in this region do have advanced medical facilities.
Key Players
The key players of global stroke disorder and treatment market include AstraZeneca {United Kingdom (UK)}, Bayer Pharma AG (Germany), Daiichi Sankyo (Japan), Novartis AG (Switzerland), and Pfizer {United States of America (US)}.
Latest Industry News
  • The US Food & Drug Administration (FDA) has approved the use of the Trevo clot retrieval device for up to 24 hours after symptom onset in certain patients presenting with acute ischemic stroke. The device has been indicated as initial therapy for ischemic stroke when used in conjunction with tissue plasminogen activator (TPA). Earlier, the use of this device was approved for use within 6 hours of symptom onset. 15 FEB 2018
  • BrainQ, an Israel-based startup aims to help stroke victims and those with spinal cord injuries treat their injuries. Their plan to achieve their goal is by offering personalized electromagnetic treatment protocol. They have raised the US $ 5.3 mn for the same. The general idea behind BrainQ is to use the patient’s brainwaves to generate a tailored treatment protocol. 15 MAY 2018.
Access Report @ https://www.marketresearchfuture.com/reports/stroke-disorder-treatment-market-1651

Saturday, 2 May 2020

Global Ventilator-Associated Pneumonia Market Solid Segment Analyzed By Latest Trends, Growth Rate And 2025 Insight

Market Scenario
According to CDC in 2013, there were 2.8 million traumatic brain injury visits to emergency department and hospitals. The emergency department visits of brain injury patients increased by 47% from 2007. Thus, increasing incidence of TBI drives the growth of the market. Furthermore, increasing geriatric population is likely to fuel the market to grow.  According to the U.S. Census Bureau in 2015, 47.8 million people were 65 years or older, and in 2060, 98.2 million are expected to be 65 years or older.  Such increasing trend in the geriatric population provides favorable backgrounds for the market to grow.
Ventilator-associated pneumonia is a type of lung infection caused to patients who are on ventilators. Ventilator-associated pneumonia is caused mainly due to lung disease, neurologic disease, and trauma to critically ill persons. Diagnosing VAP requires aggressive surveillance combined with the radiographic examination, bedside examination, and microbiologic examinations of respiratory secretions. Growing Intensive Care Unit Admissions due to rising prevalence of respiratory diseases, rising number of ICU beds and high incidence of traumatic injuries provides favorable backgrounds for the market to grow.
However, factors such as expensive diagnostic tests, high ventilator charges, inappropriate reimbursement scenario, risks associated with ventilators are expected to restrict the market growth during the forecast period.
Key players
Some of the key players contributing in the global Ventilator-associated pneumonia market industry are Merck & Co., Inc. (U.S.), Adenium Biotech ApS (Denmark), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Austria) and other.
Segmentation
The global Ventilator-associated pneumonia market is segmented on the basis of diagnosis, mode of treatment, and end-user. The Ventilator-associated pneumonia market, by diagnosis categorized into Clinical Examination, Radiological Examination, Microbiological Analysis and others. Microbiological Analysis is further sub-segmented into Blood and pleural fluid cultures, Nonquantitative or semi-quantitative airway sampling and Quantitative cultures of airway specimens. Mode of treatment segment is segmented into Homecare, Hospital care, and others. On the basis of end-user, the market is segmented into Hospitals & Clinics, Research centers, Ambulatory Care Centers and Emergency Medical Services (EMS).      
Regional Market Summary
The Ventilator-associated pneumonia market is dominated by North America owing to the rising geriatric population within the region. The U.S. Census Bureau projected that in 2060, 19.7 million would be of age 85 or older. This influences the growth of this market in this region.
Asia Pacific was projected to be the fastest growing region for the global Ventilator-associated pneumonia market in 2017. The rising geriatric population, increasing healthcare expenditure and growing respiratory disorders in Asia is expected to drive market growth in this region. According to The Asian Development Bank (ADB), the geriatric population in Asia is estimated to reach 923 million by 2050. Thus, this provides favorable backgrounds for the Ventilator-associated pneumonia market to grow.
It is estimated that Europe stood second in the global Ventilator-associated pneumonia market owing to increasing prevalence of lung diseases. According to European respiratory society, more than 50% of deaths are due to lung diseases. Thus, increasing prevalence of lung diseases in this region influences the growth of this market in this region.
The Middle East and Africa holds the least share in the global Ventilator-associated pneumonia market due to the presence of stringent government policies, poor economies, under-developed healthcare infrastructure and low penetration of healthcare services, especially within the African region.